Merck & Co (MRK) Stock Price
Merck & Co Price
Merck & Co (MRK) Stock | ISIN US58933Y1055 | WKN A0YD8Q. The current Merck & Co stock price is 119.52 USD (2026). Revenue is 67.39 B USD. Net income is 13.56 B USD. The P/E ratio is 22.09. Market capitalization is 299.64 B USD. Merck & Co operates in the Health sector.
Merck & Co stock price
Details
Stock Price
ⓘHow to Read This Chart
This chart tracks the historical stock price of Merck & Co over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.
Total Return vs. Price Return
The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.
Intraday Price Data
When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Merck & Co stock reacts to market openings, earnings releases, or breaking news throughout the trading session.
What to Look For
Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Merck & Co's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.
| Date | Merck & Co Price |
|---|
Merck & Co Revenue, EBIT, Net Income
3 Years
5 Years
10 Years
25 Years
Max
Details
Merck & Co Income Statement, Balance Sheet, Cash Flow Statement
| REVENUE (M USD) |
|---|
| REVENUE GROWTH (%) |
| GROSS MARGIN (%) |
| GROSS INCOME (M USD) |
| NET INCOME (M USD) |
| NET INCOME GROWTH (%) |
| DIVIDEND (USD)DIV. (USD) |
| DIVIDEND GROWTH (%)DIV. GROWTH (%) |
| SHARES (M) |
| DOCUMENTS |
Details
Income Statement Key Figures
ⓘRevenue and Revenue Growth
Revenue is the starting point of every income statement — it measures the total sales Merck & Co generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.
Gross Margin
Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Merck & Co retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Merck & Co's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.
EBIT and EBIT Margin
EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.
Net Income and Earnings Per Share (EPS)
Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.
Shares Outstanding
The total number of shares Merck & Co has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.
Analyst Estimates
The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Merck & Co's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.
Merck & Co stock margins
3 Years
5 Years
10 Years
25 Years
Max
Details
Merck & Co Stock Revenue, EBIT, Earnings per Share
3 Years
5 Years
10 Years
25 Years
Max
Details
Merck & Co business model & stock analysis
Merck & Co SWOT Analysis
Strengths
Merck & Co Inc, a leading pharmaceutical company, possesses the following strengths:
- Strong brand reputation and recognition worldwide
- Extensive experience and expertise in drug development and research
- Robust portfolio of patented drugs and intellectual property
- Broad geographical presence, with operations in numerous countries
- Diverse product offerings across multiple therapeutic areas
Merck & Co Inc faces the following weaknesses:
- Dependency on a limited number of flagship drugs for significant revenue
- Relatively high research and development costs
- Vulnerability to generic competition as patents expire
- Regulatory challenges and delays in drug approvals
- Potential exposure to litigation related to product safety and side effects
Merck & Co Inc can explore the following opportunities:
- Expansion into emerging markets with growing healthcare needs
- Investment in research and development of innovative drugs and therapies
- Strategic collaborations and partnerships for joint ventures and licensing
- Advancements in technology for drug delivery and precision medicine
- Increasing demand for personalized healthcare solutions
Merck & Co Inc faces the following threats:
- Intense competition from other major pharmaceutical companies
- Economic and political fluctuations impacting global markets
- Stringent regulations and compliance requirements
- Potential disruption caused by unforeseen events, such as pandemics
- Negative public perception and skepticism towards the pharmaceutical industry
Weaknesses
Merck & Co Inc faces the following weaknesses:
- Dependency on a limited number of flagship drugs for significant revenue
- Relatively high research and development costs
- Vulnerability to generic competition as patents expire
- Regulatory challenges and delays in drug approvals
- Potential exposure to litigation related to product safety and side effects
Merck & Co Inc can explore the following opportunities:
- Expansion into emerging markets with growing healthcare needs
- Investment in research and development of innovative drugs and therapies
- Strategic collaborations and partnerships for joint ventures and licensing
- Advancements in technology for drug delivery and precision medicine
- Increasing demand for personalized healthcare solutions
Merck & Co Inc faces the following threats:
- Intense competition from other major pharmaceutical companies
- Economic and political fluctuations impacting global markets
- Stringent regulations and compliance requirements
- Potential disruption caused by unforeseen events, such as pandemics
- Negative public perception and skepticism towards the pharmaceutical industry
Opportunities
Merck & Co Inc can explore the following opportunities:
- Expansion into emerging markets with growing healthcare needs
- Investment in research and development of innovative drugs and therapies
- Strategic collaborations and partnerships for joint ventures and licensing
- Advancements in technology for drug delivery and precision medicine
- Increasing demand for personalized healthcare solutions
Merck & Co Inc faces the following threats:
- Intense competition from other major pharmaceutical companies
- Economic and political fluctuations impacting global markets
- Stringent regulations and compliance requirements
- Potential disruption caused by unforeseen events, such as pandemics
- Negative public perception and skepticism towards the pharmaceutical industry
Threats
Merck & Co Inc faces the following threats:
- Intense competition from other major pharmaceutical companies
- Economic and political fluctuations impacting global markets
- Stringent regulations and compliance requirements
- Potential disruption caused by unforeseen events, such as pandemics
- Negative public perception and skepticism towards the pharmaceutical industry
Merck & Co Segments
Merck & Co Revenue by Segment (1/3)
3 Years
5 Years
10 Years
Max
Details
Merck & Co Revenue by Segment (2/3)
3 Years
5 Years
10 Years
25 Years
Max
Details
Merck & Co Revenue by Segment (3/3)
3 Years
5 Years
10 Years
Max
Details
Merck & Co Revenue by Region
3 Years
5 Years
10 Years
Max
Details
Merck & Co Eulerpool Fair Value
Merck & Co historical P/E ratio, EBIT multiple, and P/S ratio
Merck & Co annual returns
Details
Annual Return
ⓘWhat This Chart Shows
This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.
Price Return
Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.
Dividend Return
Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.
What to Look For
Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.
Merck & Co shares outstanding
3 Years
5 Years
10 Years
25 Years
Max
Details
Merck & Co Dividend History
37 years of dividend payments · 15 consecutive increases
Merck & Co dividend history and estimates
3 Years
5 Years
10 Years
25 Years
Max
Details
Merck & Co dividend payout ratio
3 Years
5 Years
10 Years
25 Years
Max
Details
Merck & Co Earnings Calls
Merck & Co Earnings Estimates
Merck & Co Earnings Estimates
| Date | EPS estimate | Revenue Estimate | Quarterly report |
|---|---|---|---|
| 4/30/2026 | -1.53USD | 16.04 BUSD | 2026 Q1 |
| 2/3/2026 | 2.03USD | 16.36 BUSD | 2025 Q4 |
| 4/25/2024 | 1.98USD | 15.15 BUSD | 2024 Q1 |
| 2/1/2024 | 0.13USD | 14.66 BUSD | 2023 Q4 |
| 8/1/2023 | 1.88USD | 14.93 BUSD | 2023 Q2 |
| 4/27/2023 | 1.78USD | 14.35 BUSD | 2023 Q1 |
| 2/2/2023 | 1.54USD | 13.83 BUSD | 2022 Q4 |
| 10/27/2022 | 1.72USD | 14.29 BUSD | 2022 Q3 |
| 7/28/2022 | 1.72USD | 14.11 BUSD | 2022 Q2 |
| 4/28/2022 | 1.85USD | 14.9 BUSD | 2022 Q1 |
EESG©
Eulerpool ESG Scorecard© for the Merck & Co stock
EEnvironment
20
Environment
SSocial
20
Social
GGovernance (Corporate Governance)
4
Governance (Corporate Governance)
The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.
Merck & Co shareholder structure
| % | Name |
|---|---|
10.04207% | |
5.6954% | |
4.72652% | |
3.06568% | |
2.35152% | |
2.1486% | |
1.44042% | |
1.13606% | |
0.99775% | |
0.90891% |
Merck & Co Executives and Management Board
Mr. Robert Davis
(58)Chairman of the Board, President, Chief Executive Officer · since 2014
Mr. Chirfi Guindo
(59)Senior Vice President, Chief Marketing Officer - Human Health
Ms. Betty Larson
(49)Chief Human Resources Officer, Executive Vice President
Dr. Dean Li
(63)Executive Vice President, President - Merck Research Laboratories · since 2021
Mr. Richard Deluca
(62)Executive Vice President, President - Merck Animal Health
Merck & Co Supply Chain
Frequently asked questions about Merck & Co
The business model of Merck & Co Inc is centered around the development, manufacturing, and marketing of innovative pharmaceutical products and vaccines. Merck's primary aim is to improve and save lives by addressing unmet medical needs. Through rigorous research and development, the company focuses on discovering novel therapies and delivering them to patients worldwide. Merck operates across various therapeutic areas, including oncology, infectious diseases, vaccines, cardiovascular health, and more. By combining scientific expertise with a strong commitment to patients and healthcare professionals, Merck continually strives to advance medical science and make a positive impact on global health.
Merck & Co stock
Merck & Co Peer Group
Merck & Co Ticker
Merck & Co FIGI
All fundamentals and in-depth analysis of Merck & Co
Our stock analysis for Merck & Co Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merck & Co Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.